Resistance emergence to zidovudine (ZDV) and lamivudine (3TC(TM)) in HIV-1-infected patients in an ongoing open label trial

被引：0

作者：

Rusconi, S ^{[1
]}

dePasquale, MP ^{[1
]}

Milazzo, L ^{[1
]}

Moscatelli, G ^{[1
]}

Kurtagic, S ^{[1
]}

dArminioMonforte, A ^{[1
]}

Galli, M ^{[1
]}

机构：

[1] UNIV MILAN,LUIGI SACCO HOSP,INFECT DIS UNIT,I-20122 MILAN,ITALY

来源：

AIDS | 1996年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：P6 / P6

页数：1

共 50 条

[21] Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
Zhou, XJ
Havlir, DV
Richman, DD
Acosta, EP
Hirsch, M
Collier, AC
Tebas, P
Sommadossi, JP
[J]. AIDS, 2000, 14 (18) : 2869 - 2876
[22] Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
Staszewski, S
Miller, V
Rehmet, S
Stark, T
DeCree, J
DeBrabander, M
Peeters, M
Andries, K
Moeremans, M
DeRaeymaeker, M
Pearce, G
VanDenBoeck, R
Verbiest, W
Stoffels, P
[J]. AIDS, 1996, 10 (05) : F1 - F7
[23] IN-VIVO COMPARISON OF ZIDOVUDINE RESISTANCE MUTATIONS IN BLOOD AND CSF OF HIV-1-INFECTED PATIENTS
WILDEMANN, B
HAAS, J
EHRHART, K
HAHN, M
WAGNER, H
LYNEN, N
STORCHHAGENLOCHER, B
[J]. NEUROLOGY, 1993, 43 (12) : 2659 - 2663
[24] Drug resistance and viral load in NUCA 3002: A comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs ZDV/dideoxycytidine (ddC) combination therapy in ZDV-experienced (>=24 weeks) patients (CD4 cells 100-300/mm(3))
Johnson, VA
Wagner, SF
Overbay, CB
Wagner, JR
Cammack, N
Penn, CR
Rubin, M
Bartlett, JA
Fallon, MA
Quinn, JB
Benoit, SL
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 55 - 55
[25] Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients
Chien, JW
Valdez, H
McComsey, G
McClernon, D
St Clair, M
Lederman, MM
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (04): : 277 - 280
[26] A phase III, multicenter, randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz (EFV) plus indinavir (IDV), versus EFV plus zidovudine (ZDV) plus lamivudine (3TC), versus IDV+ZDV+3TC at 36 weeks [study DMP 266-006]
Staszewski, S
Morales-Ramirez, J
Tashima, K
Hardy, D
Johnson, P
Nelson, M
Manion, D
Farina, D
Labriola, D
Ruiz, N
[J]. AIDS, 1998, 12 : S13 - S13
[27] Persistence versus Reversion of 3TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance
Rath, Barbara A.
Olshen, Richard A.
Halpern, Jerry
Merigan, Thomas C.
[J]. VIRUSES-BASEL, 2012, 4 (08): : 1212 - 1234
[28] Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
Malet, Isabelle
Delelis, Olivier
Soulie, Cathia
Wirden, Marc
Tchertanov, Luba
Mottaz, Philippe
Peytavin, Gilles
Katlama, Christine
Mouscadet, Jean-Francois
Calvez, Vincent
Marcelin, Anne-Genevieve
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (04) : 795 - 804
[29] Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis
Lu, Jing
Deeks, Steven G.
Hoh, Rebecca
Beatty, George
Kuritzkes, Benjamin A.
Martin, Jeffrey N.
Kuritzkes, Daniel R.
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) : 60 - 64
[30] Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine
Gulick, RM
Meibohm, A
Havlir, D
Eron, JJ
Mosley, A
Chodakewitz, JA
Isaacs, R
Gonzalez, C
McMahon, D
Richman, DD
Robertson, M
Mellors, JW
[J]. AIDS, 2003, 17 (16) : 2345 - 2349

← 1 2 3 4 5 →